Education
About Us
Working with TipRanks
Follow Us
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
PRCT Stock Chart & Stats
$31.92
-$0.85(-0.97%)
At close: 4:00 PM EST
$31.92
-$0.85(-0.97%)
Day’s Range― - ―
52-Week Range$30.80 - $103.81
Previous CloseN/A
Volume113.34K
Average Volume (3M)1.30M
Market Cap
$1.75B
Enterprise Value$1.77B
Total Cash (Recent Filing)$294.28M
Total Debt (Recent Filing)$78.93M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Mar 03, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding55,878,590
10 Day Avg. Volume1,753,810
30 Day Avg. Volume1,298,530
Financial Highlights & Ratios
PEG Ratio2.10
Price to Book (P/B)10.43
Price to Sales (P/S)18.70
P/FCF Ratio-40.50
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue5.91
Enterprise Value/Gross Profit9.16
Enterprise Value/Ebitda-22.89
Forecast
1Y Price Target
$54.57Price Target Upside70.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.48
Revenue Forecast (FY)$326.55M
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceQ3 revenue totaled $83.3M, up 43% from last year and comfortably ahead of the Street's $80.8M forecast.
Leadership And StrategyNew CEO Larry Wood views the current situation as an opportunity to improve utilization with better commercial onboarding strategies.
Market PositionPRCT is growing around +30% in 2026 on new estimates, right towards the top-end of MedTech, despite trading on sub 4x Sales.
Bears Say
Operational ExecutionPRCT has to show improved operational execution for confidence in FY26 numbers to improve.
Sales GuidanceShares are trading off 6% after market due to lower-than-expected handpiece utilization and lowered handpiece guidance for 2025.
Utilization ConcernsConcerns about slowing utilization, lumpy capital sales, and high expectations continue to worry investors.
PROCEPT BioRobotics News
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $30.80 and its highest was $103.81 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
PROCEPT BioRobotics’s market cap is $1.75B.
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Mar 03, 2026 which is in 114 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on Nov 04, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.412 by $0.032.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Undervalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -0.32.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 55,878,590 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.412. Following the earnings report the stock price went down -9.737%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Currently, no hedge funds are holding shares in PRCT
PROCEPT BioRobotics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.57 (70.96% Upside)
$54.57 (70.96% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 199.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $785.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 10.2%
Last 30 Days ▲ 10.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.13%
12-Months-Change
Fundamentals
Return on Equity
-27.22%
Trailing 12-Months
Asset Growth
36.72%
Trailing 12-Months
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics (PRCT) is a medical technology company focused on advancing robotic-assisted surgical solutions for urology. The company specializes in developing innovative products and services that enhance the precision and safety of surgical procedures, particularly for prostate surgery. PROCEPT’s flagship product, the AQUABEAM Robotic System, utilizes advanced robotics and real-time imaging technology to perform minimally invasive treatments with improved patient outcomes.
PRCT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects strong revenue growth and significant increases in both U.S. and international sales, alongside positive gross margin expansion. However, persistent net losses, challenges in utilization growth, and anticipated procedural headwinds present concerns. The company remains optimistic about its strategic initiatives and long-term growth potential.View all PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$54.57
▲(70.96% Upside)
Technical Analysis
Alphatec Holdings
―
Artivion
―
LivaNova
―
Inspire Medical Systems
―
SS Innovations International
―
Ownership Overview
3.06% Insiders
39.03% Mutual Funds
0.14% Other Institutional Investors
42.56% Public Companies and Individual Investors